

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)



(10) International Publication Number
WO 2022/084947 A1

(51) International Patent Classification:

C07D 215/227 (2006.01) A61K 47/54 (2017.01)
A61K 31/47 (2006.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/IB2021/059772

(22) International Filing Date:

22 October 2021 (22.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/104,160 22 October 2020 (22.10.2020) US

(71) Applicant: LUNELLA BIOTECH, INC. [CA/CA]; 145
Richmond Road, Ottawa, Ontario K1Z 1A1 (CA).

(72) Inventors: LISANTI, Michael P.; 842 Wilmslow Road,
Flat 27, Philip Godlee Lodge, Didsbury Village Greater
Manchester M20 2DS (GB). SOTGIA, Federica; 842
Wilmslow Road, Flat 27, Philip Godlee Lodge, Didsbury
Village Greater Manchester M20 2DS (GB). FIORILLO,
Marco; 1 Isaac Way, Apartment 127, Advent 3, Manches-
ter Greater Manchester M4 7EE (GB). KANGASMETSA,
Jussi; 119 Clay Farm Drive, Cambridge CB2 9BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS

ATP Heatmap gene expression
Profile from GSE36953




FIG. 1A

(57) Abstract: High ATP production by the mitochondrial ATP-synthase is a new therapeutic target for anti-cancer therapy, especially for preventing tumor progression. A mitochondrial-related gene signature for metastasis is described, which features the gamma-subunit of the mitochondrial ATP-synthase (ATP5F1C). Knock-down of ATP5F1C expression significantly reduces ATP-production, 3D anchorage-independent growth and cell migration. Administration of the Bedaquiline, or a Bedaquiline derivative with a fatty acid moiety, down-regulates ATP5F1C expression in vitro and prevents spontaneous metastasis in vivo. Mitochondrial ATP5F1C is a promising new biomarker and molecular target for future drug development, for the prevention of metastatic disease progression.

WO 2022/084947 A1